Possible impact of MADCAM1 gene single nucleotide polymorphisms to the outcome of allogeneic hematopoietic stem cell transplantation

Possible impact of MADCAM1 gene single nucleotide polymorphisms to the outcome of allogeneic hematopoietic stem cell transplantation
复制标题

DOI:
10.1016/j.humimm.2009.03.008
复制
发表时间:
2009-06-01
期刊:
影响因子:
2.7
通讯作者:
Petrek, Martin
Petrek, Martin
中科院分区:
医学4区
文献类型:
--
作者:
Arnbruzova, Zuzana;Mrazek, Frantisek;Petrek, Martin

文献摘要

被引文献

相似文献

粘膜地址素细胞粘附分子-1 (MAdCAM-1) 有助于在同种异体造血干细胞移植 (aHSCT) 后将供体 T 细胞募集到受体的粘膜组织中。我们研究的目的是确定 MADCAM1 基因的选定单核苷酸多态性 (SNP) 是否与 aHSCT 后严重并发症的发生有关。通过聚合酶链反应,使用序列特异性引物对 87 个捷克 HLA 相同的供体-受体 aHSCT 对中的三个 MADCAM1 基因单核苷酸多态性(rs758502 C/T、rs2302217 A/G、rs3745925 G/T)进行基因分型。 MADCAM1 rs2302217 AA 纯合受者比其他基因型患者更容易发生慢性 GVHD(65% vs. 34%;p = 0.025)。此外。多变量分析显示,受体中的 MADCAM1 rs2302217 AA 基因型也是与急性 GVHD 发生(p = 0.036)和总生存期降低(p = 0.001)相关的独立因素。这些数据表明,MADCAM1 基因多态性可能与慢性 GVHD 风险相关,并且还可能影响与 aHSCT 相关的死亡率。 (C) 2009 年美国组织相容性和免疫遗传学学会。由爱思唯尔公司出版。保留所有权利。
Mucosal addressin cell adhesion molecule-1 (MAdCAM-1) contributes to the recruitment of donor T cells into the mucosal tissues of the recipient after allogeneic hematopoietic stem cell transplantation (aHSCT). The at m Of Our study was to determine whether selected single nucleotide polymorphisms (SNPs) of the MADCAM1 gene are associated with development of serious complications after aHSCT. Three MADCAM1 gene single nucleotide polymorphisms (rs758502 C/T, rs2302217 A/G, rs3745925 G/T) were genotyped by polymerase chain reaction with sequence-specific primers in 87 Czech, HLA-identical donor-recipient aHSCT pairs. MADCAM1 rs2302217 AA homozygous recipients developed chronic GVHD more frequently than patients with other genotypes (65% vs. 34%; p = 0.025). Furthermore. multivariate analysis revealed the MADCAM1 rs2302217 AA genotype in recipient being also an independent factor associated with development of acute GVHD (p = 0.036) and decreased overall survival (p = 0.001). These data Suggest that MADCAM1 gene polymorphisms may be associated with the risk of chronic GVHD and may, also, affect mortality related to aHSCT. (C) 2009 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.